Short Interest in Addex Therapeutics Ltd (NASDAQ:ADXN) Drops By 50.0%

Addex Therapeutics Ltd (NASDAQ:ADXNGet Rating) was the target of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 100 shares, a drop of 50.0% from the March 15th total of 200 shares. Based on an average daily trading volume, of 3,100 shares, the short-interest ratio is presently 0.0 days.

Shares of NASDAQ ADXN opened at $4.39 on Friday. The company has a market capitalization of $47.73 million, a P/E ratio of -1.54 and a beta of 1.82. Addex Therapeutics has a 52-week low of $4.27 and a 52-week high of $11.48. The company’s 50 day moving average price is $5.12 and its 200-day moving average price is $6.49.

ADXN has been the topic of a number of recent analyst reports. HC Wainwright dropped their price target on shares of Addex Therapeutics from $28.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, February 11th. Zacks Investment Research downgraded shares of Addex Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 28th.

Addex Therapeutics Company Profile (Get Rating)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.

Featured Articles

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.